Similar articles

• Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.

  Roehrborn CG. Roehrborn CG. BJU Int. 2006 Apr;97(4):734-41. doi: 10.1111/j.1464-410X.2006.06110.x. BJU Int. 2006. PMID: 16536764 Clinical Trial.
• Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

  Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G. Emberton M, et al. J Urol. 2006 Sep;176(3):1051-6. doi: 10.1016/j.juro.2006.04.044. J Urol. 2006. PMID: 16890690
• Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

  van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. van Kerrebroeck P, et al. Eur Urol. 2000 Mar;37(3):306-13. doi: 10.1159/000052361. Eur Urol. 2000. PMID: 10720857 Clinical Trial.
• Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.

  McKeage K, Plosker GL. McKeage K, et al. Drugs. 2002;62(4):633-53. doi: 10.2165/00003495-200262040-00009. Drugs. 2002. PMID: 11893233 Review.
• Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

  Wilde MI, Fitton A, McTavish D. Wilde MI, et al. Drugs. 1993 Mar;45(3):410-29. doi: 10.2165/00003495-199345030-00008. Drugs. 1993. PMID: 7682910 Review.